XLON
OBD
Market cap3mUSD
Oct 09, Last price
0.10GBP
1D
-4.76%
1Q
0.00%
Jan 2017
-99.93%
IPO
-99.94%
Name
Oxford Biodynamics PLC
Chart & performance
P/E
—
P/S
1.95
EPS
—
Div yield, %
—
Shrs. gr., 5y
71.84%
Rev. gr., 5y
19.15%
Revenues
1m
+72.17%
Net income
-11m
L-3.58%
CFO
-8m
L-24.21%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Oxford, United Kingdom, and established in 2007, Oxford BioDynamics Plc operates as a biotechnology enterprise. The company's primary focus lies in the discovery and development of biomarkers for the pharmaceutical and biotechnology industries, serving both domestic and international markets, with a significant presence in the United States. Central to its operations is EpiSwitch, a proprietary technology platform. This platform facilitates the identification, evaluation, validation, and continuous monitoring of epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These biomarkers are utilized in various applications, including medical testing kits, predicting disease onset or progression, aiding in diagnosis, and informing treatment approaches. Among its innovative products are the EpiSwitch CiRT, a validated prognostic tool for anticipating patient response to checkpoint inhibitor immunotherapy; the EpiSwitch CST, an advanced blood assay designed to forecast the severity of COVID-19 in adult patients; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome profiling and the identification of new biomarkers.
Key people
Stephen Diggle
Non-Executive Chairman of the Board · since 2019
Aroul Ramadass
Chief Technology Officer
Alexandre Akoulitchev
Chief Scientific Officer, Executive Director
Ewan Hunter
Director - Business Development
Susan Steven
Company Secretary
Non-Executive Independent Director · since 2019
Alison Kibble
Non-Executive Independent Director · since 2016
Headquarters & legal address
3140 ROWAN PLACE, JOHN SMITH DRIVE
OXFORD BUSINESS PARK SOUTH
OXFORD, OXF OX4 2WB
GB
OXFORD BUSINESS PARK SOUTH
OXFORD, OXF OX4 2WB
GB
Previous name
OXFORD BIODYNAMICS LIMITED
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||